INCB 62079
Alternative Names: INCB-062079; INCB-62079Latest Information Update: 25 Oct 2021
Price :
$50 *
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cholangiocarcinoma; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Ovarian cancer
Most Recent Events
- 13 Jul 2020 Discontinued - Phase-I for Cholangiocarcinoma in Belgium (unspecified route) (NCT03144661) (Incyte Corporation pipeline, July 2020)
- 13 Jul 2020 Discontinued - Phase-I for Cholangiocarcinoma in USA (unspecified route) (NCT03144661) (Incyte Corporation pipeline, July 2020)
- 13 Jul 2020 Discontinued - Phase-I for Liver cancer (Late-stage disease) in Belgium (unspecified route) (NCT03144661) (Incyte Corporation pipeline, July 2020)